MedTrace Logo

Abemaciclib in Patients with Oligodendroglioma

NCT03969706 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-11-18

No results posted yet for this study

Summary

This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma

Conditions

  • Oligodendroglioma, Adult

Interventions

DRUG

Abemaciclib 200 MG

Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    collaborator OTHER

  • University of Pennsylvania

    collaborator OTHER

  • Stephen Bagley, MD, MSCE

    lead OTHER

Principal Investigators

  • Stephen Bagley, MD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2025-05-15
Completion
2027-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03969706 on ClinicalTrials.gov